CRISPR (CRSP) Rated Overweight on Gene Editing Growth

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) to $110 from $105 on March 17, retaining an Overweight rating in response to the company’s convertible note issuance. CRISPR Therapeutics AG (NASDAQ:CRSP) raised $600 million in convertible notes due in March 2031, convertible at $76.56 per share and with an effective interest rate of 1.73%. The company also allowed initial purchasers to pick up an extra $50 million in notes, with the transaction set to finalize in March of this year.

Moreover, CRISPR Therapeutics AG (NASDAQ:CRSP) plans to disclose Phase I data on zugo-cel in autoimmune diseases and B-cell lymphoma in the latter half of 2026. The company also plans to begin Phase I research on CTX340 in the first half of 2026 and CTX460 in mid-2026.

Meanwhile, in the second half of 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) will provide Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in patients undergoing total knee replacement.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology, using its proprietary gene sequencing platform to develop precise treatments for diseases requiring DNA modification.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.